CME TTR Amyloidosis Treating and Empowering the Patient Mo Mori - PowerPoint PPT Presentation

Feb 24, 2023 •126 likes •210 views

CME TTR Amyloidosis Treating and Empowering the Patient Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic Treatment Options Symptom relief Liver transplantation TTR stabilizers Tafamidis Diflunisal Tetramer Monomer

CME TTR Amyloidosis Treating and Empowering the Patient Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic
Treatment Options • Symptom relief • Liver transplantation • TTR stabilizers • Tafamidis • Diflunisal Tetramer Monomer Misfolded protein Amyloid fibrils • TTR production blockers • Inotersen • Patisiran
Managing TTR Amyloidosis is a Team Effort Educating Patients • Long-term management • Compliance Team approach to care • Cardiologists • Nephrologists • Neurologists • Gastrointestinal specialists • Ophthalmologists • Genetic counselors • General practitioners • Nurses
Amyloidosis Support Groups amyloidosissupport.org • Treatment centers • Local chapters • Events • New • Resources • Clinical trail Information • Amyloidosis information
Amyloidosis Research Consortium arci.org • Research • Events • Treatment centers • Patient support resources • Clinical trail Information • Amyloidosis information • My Amyloidosis Pathfinder (MAP)
Amyloidosis Foundation amyloidosis.org • Facts • Research • Toolkits • Webinars • Support material • Stories
Summary TTR Amyloidosis is: • No longer a death sentence • Manageable and treatable @moriegertz • Rare but not as rare as we assume • Awareness campaigns are available • Support is available

Recommend

Targe&ng Macrophages in Amyloidosis Mario Nuvolone Amyloidosis

Targe&ng Macrophages in Amyloidosis Mario Nuvolone Amyloidosis Research and Treatment Center Founda9on IRCCS Policlinico San Ma=eo University of Pavia,

252 views • 24 slides

CME TTR Amyloidosis Confirming a Diagnosis Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo

CME TTR Amyloidosis Confirming a Diagnosis Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic When to Suspect TTR Amyloidosis Family History Carpal Tunnel Cardiomyopathies Conceio et al. J Peripher Nerv Syst. 2016;21(1):5-9. Red

111 views • 7 slides

Amyloidosis Nelson Leung, MD Mayo Clinic Rochester FOURTH INTERNATIONAL CONGRESS ON

Amyloidosis Nelson Leung, MD Mayo Clinic Rochester FOURTH INTERNATIONAL CONGRESS ON IMMUNOINTERVENTION IN NEPHROLOGY Cagliari, 30 April- 3 May 2011 Outline History AL AA Hereditary amyloidosis History of Amyloidosis

673 views • 56 slides

CME TTR Amyloidosis Th The Undiagnosed Patient (and how to find them) m) Mo Mori rie A Gert

CME TTR Amyloidosis Th The Undiagnosed Patient (and how to find them) m) Mo Mori rie A Gert rtz, z, MD MD: Ma Mayo Clinic TTR Amyloidosis: Epidemiology > 50,000 worldwide ~ 10,000 with FAP > 40,000 with FAC Assumed to

390 views • 10 slides

Cardiac amyloidosis: An emerging target in HFpEF? Peter van der Meer, MD Groningen, The

Cardiac amyloidosis: An emerging target in HFpEF? Peter van der Meer, MD Groningen, The Netherlands May, 2019 - Athens, Greece Amyloidosis Cardiac amyloidosis: An emerging target in HFpEF? Peter van der Meer Universitair Medisch Centrum

406 views • 21 slides

TranstHyretin Amyloidosis Outcome Survey Agenda: What is ATTR ? What is THAOS ?

TranstHyretin Amyloidosis Outcome Survey Agenda: What is ATTR ? What is THAOS ? How can we use THAOS to expand our knowledge of ATTR- related amyloidosis and to improve diagnosis and management ? Apo A immunoglobulin Lysozime

586 views • 33 slides

Nutritional Aspects in ATTR-Amyloidosis Anna Hsing-Kabar Medizinische Klinik B fr

2ND EUROPEAN ATTR AMYLOIDOSIS MEETING FOR PATIENTS AND DOCTORS 02.09.2019 Nutritional Aspects in ATTR-Amyloidosis Anna Hsing-Kabar Medizinische Klinik B fr Gastroenterologie und Hepatologie Universittsklinikum Mnster Is there a special

428 views • 23 slides

Amyloidosis Nelson Leung Mayo Clinic (Rochester MN USA) Discussant: Sonia Pasquali (Reggio

Amyloidosis Nelson Leung Mayo Clinic (Rochester MN USA) Discussant: Sonia Pasquali (Reggio Emilia Italy) Amyloidosis EFFECTIVE THERAPY Amyloidoses are treatable (curable?) Palladini G, Merlini G Haematologica, 94: 1004 - 2009

793 views • 34 slides

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With

Histologic and Molecular Correlates in Patients with AL Amyloidosis in Remission But With Persistent Renal Disease Cindy Varga, MD Assistant Professor Tufts Medical Center May 23 rd , 2019 International Kidney and Monoclonal Gammopathy

373 views • 19 slides

MANAGEMENT OF PATIENTS WITH FIRST RELAPSE NON IgM LIGHT CHAIN AMYLOIDOSIS: A FRENCH MULTICENTRIC

MANAGEMENT OF PATIENTS WITH FIRST RELAPSE NON IgM LIGHT CHAIN AMYLOIDOSIS: A FRENCH MULTICENTRIC RETROSPECTIVE STUDY Camille Villesuzanne 1 , Stephanie Harel MD 2 , Alexis Talbot, MD 2 , Bruno Royer MD 2 , Naelle Lombion MD 2 , Fabien Lebras MD 3

523 views • 19 slides

Interessamento cardiaco da deposi( di amiloide Giovanni Palladini Amyloidosis Research and

Cardiopa(e nel paziente emopa(co Interessamento cardiaco da deposi( di amiloide Giovanni Palladini Amyloidosis Research and Treatment Center Fondazione IRCCS Policlinico San Ma<eo and Department of Molecular Medicine University of Pavia

477 views • 21 slides

in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti- Amyloid mAb CAEL-101

Improvement in Global Longitudinal Strain (GLS) correlates with NT-proBNP response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti- Amyloid mAb CAEL-101 Divaya Bhutani MD, Sofia Shames, MD, Jeff Goldsmith, PhD, Siyang

247 views • 20 slides

THAOS: TranstHyretin Amyloidosis Outcomes Survey: an international Registry Presenter: Prof

Clinical trial and registry Update II THAOS: TranstHyretin Amyloidosis Outcomes Survey: an international Registry Presenter: Prof Claudio Rapezzi Discussant: Dr Philippe Charron Centre de Rfrence pour les Maladies cardiaques hrditaires,

277 views • 7 slides

Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study

Long-term Safety and Efficacy of Patisiran in Patients with hATTR Amyloidosis: Global OLE Study Michael Polydefkis 1 , Alejandra Gonzlez-Duarte 2 , T eresa Coelho 3 , Jonas Wixner 4 , Arnt Kristen 5 , Hartmut Schmidt 6 , John L Berk 7 , Quinn

385 views • 12 slides

AMYLOIDOSIS Corporation and Millennium Pharmaceuticals Speakers Bureau for Celgen Ann

2/27/2014 Disclosures for Ann McNeill Consultant / Advisor for Celgene AMYLOIDOSIS Corporation and Millennium Pharmaceuticals Speakers Bureau for Celgen Ann McNeill, MSN, APN Corporation, Millennium Nurse Practitioner

536 views • 8 slides

Light chain deposition disease (LCDD) and renal light chain (AL) amyloidosis: different clinical

Light chain deposition disease (LCDD) and renal light chain (AL) amyloidosis: different clinical presentation and renal outcome. Paolo Milani 1 , Tamara Berno 2 , Holly Lee 3 , Marco Basset 1 , Marcello Riva 2 , Mario Nuvolone 1 , Victor

380 views • 12 slides

ATTR-CM: casustiek en behandelopties Peter van der Meer Universitair Medisch Centrum Groningen

Amyloidosis ATTR-CM: casustiek en behandelopties Peter van der Meer Universitair Medisch Centrum Groningen University Medical Center Groningen Amyloidosis Disclosures Consulting Fees: Novartis, Vifor Pharma, Servier, Pfizer Research

302 views • 17 slides

Organ transplantation in AL Amyloidosis Andrea Havasi, MD Boston University Renal Section

Organ transplantation in AL Amyloidosis Andrea Havasi, MD Boston University Renal Section Disclosure of Conflict of Interest I do not have a relationship with a for-profit and/or a not-for- profit organization to disclose Renal Involvement

443 views • 42 slides

COST-EFFECTIVENESS OF THERAPY FOR AMYLOID CARDIOMYOPATHY William Bommer MD FACC FACP Right Care

COST-EFFECTIVENESS OF THERAPY FOR AMYLOID CARDIOMYOPATHY William Bommer MD FACC FACP Right Care Initiative October 12, 2020 Disclosures:Pfizer THERAPY FOR AMYLOIDOSIS Chemotherapy and Stem Cell transplant: AL amyloidosis

417 views • 12 slides

Amiloidosi AL: clinica, esami diagnostici e prognosi Giovanni Palladini Progetto Ematologia

Titolo relazione Amiloidosi AL: clinica, esami diagnostici e prognosi Giovanni Palladini Progetto Ematologia Romagna Amyloidosis: protein misfolding disease Amyloidosis: protein misfolding disease Titolo relazione Progetto Ematologia

446 views • 23 slides

Overview Infiltrative cardiomyopathies are characterized by the deposition of abnormal

10/10/2015 Infiltrative Cardiomyopathies Focus on cardiac amyloidosis Van N Selby, MD Assistant Professor of Medicine UCSF Advanced Heart Failure and Heart Transplant Program October 9, 2015 Overview Infiltrative cardiomyopathies are

395 views • 17 slides

Final Analysis of the Phase 1a/b Study of Fibril-Reactive Monoclonal Antibody 11-1F4 (CAEL-101)

Final Analysis of the Phase 1a/b Study of Fibril-Reactive Monoclonal Antibody 11-1F4 (CAEL-101) in Patients with AL Amyloidosis Camille V. Edwards 1 , Divaya Bhutani 2 , Markus Mapara 2 , Jai Radhakrishnan 3 , Sofia Shames 4 , Mathew S. Maurer 4

169 views • 15 slides

Make it count Technical considerations and initial findings for accurate quantitative comparison

Make it count Technical considerations and initial findings for accurate quantitative comparison of urinary extracellular vesicles to determine minimal residual kidney disease in AL amyloidosis Marina Ramirez Alvarado, PhD Department of

901 views • 27 slides

With Heart Failure Diagnosis and Management of Amyloid Associated HF Jonathan Howlett Libin

Novel Treatment Strategies for Patients With Heart Failure Diagnosis and Management of Amyloid Associated HF Jonathan Howlett Libin Cardiovascular Institute Comparison of Subtypes of Amyloid Cardiomyopathy Amyloid Type Systemic Amyloidosis

456 views • 6 slides